Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
So Bantham suckers and delusional dreamers’
As opposed to duplicitous liars who will state anything to drive the price down for their personal satisfaction having lost money (just sad), or to drive the price lower to buy in or because they are short.
Which of these are you?
Again an impressive result… I do wonder why it’s taken 2 years to get this published, but perhaps there are analytical issues I do not understand. With results that good if correlated with clinical outcome it will be impossible to ignore by health professionals and guarantees a significant future for the tech…..And suggests the current research has the correct commercial focus.
So all the pessimists yesterday - where are you?
This is exactly the sort of deal we have been waiting for the over the last 5 years. Some immediate cash, another tranche soon and then €15m over the next 18m (most likely 2024). It’s the kind of deal that has been impossible to get over the line in the U.K., but with Idex as a partner not the minnow shiesters they had to deal with its across the line.
A subdued reaction IMO, traders with inside info out this morning. Should raise the mcap back towards £50m before further deals. Breathing space so they don’t have to accept a lesser deal in Italy…. clear figures.
Well done!
Apple ‘arcade’ advertising in Bids exclusive games in USA… The valuation is madness!
Dibs - ‘Talk of the NHS is pretty irrelevant here’
It is until there is a clinically verified assay. If parsotix can be used for real time PDL1/immunotherapy response for instance the U.K. lab would suddenly be very busy… And profit would certainly follow in short order….
There no point focussing on the numbers… We know they are terrible…
But there is quite a lot of information that was new to me; particularly the 2 new assays for immunotherapy (PDL1) and DNA mismatch agents (I forget the ligand).
Clearly a roll out plan for the labs that has been well thought out - difficult to say whether it could have been done any quicker.
Also clarity that for the tests most likely to come on line at the beginning a strong commercial partner/piggy back onto an established test had been sought to expedite scale and revenue.
Better than I thought anyway!
f they do pull off the development of this assay it would be very significant clinically… Her-2 low is now big business in breast cancer… Several hundred thousand tests/year I would think (poss millions), and a pharma tie up to market the test would be almost inevitable.
As It is I am pleased there is some revenue generated!
Well well well, to paraphrase Churchill ‘we are at the end of the beginning’….
No finance from eqt, in Italy, so whatever our misgivings/anxieties about whether Tuscany is working clearly those with the ability to do the due diligence locally don’t share that concern.
Also massive engineering/infrastructure partners… (Linde, etc).
Financial close over the horizon… With companies who have the cash flow to move forward quickly…
It’s scarcely believable that an 11m grant for a 30MWh project and I think the 11m is about 2/5th of the funding….But it only improves the sp/mcap by 10%… The hard money always follows the soft money - no brainer if you are a big utility company, get a valuable asset half price.
As I’ve commented before the only subsidy really required is that the govt need to buy the vanadium. They can have it back after 25 years and it will be as/more valuable and will rise index linked - hell it may even form the basis of my children’s pensions (rather than the current ‘hot air’)
Monteacute, Indeed.
Especially when the placing was at no significant discount to the sp at the time and half of it was from a company that bought a considerable stake.
Incredible in the current environment (which was even more volatile in Oct 22).
May I suggest that anyone who doesn’t understand why Parsortix is superior needs to look up ‘genotype v phenotype’.
ctDNA looks at genotype
Parsortix looks at phenotype. looking at the actual cells is going to be the critical test to determine treatment biomarkers/likely response to therapy/diagnostics…. Which is where the tech will sit.
ctDNA great for screening…. A very big market. There is lots of space for both technologies.
Yes well at some point in the near-ish future it’s going to break out of its current trading range…. I would suggest to the upside given the evidenced but not officially released evidence of progress and proximity to new isa allowances… But only time will tell.
So I think the MMs are significantly short here following Mondays rise where they position was started thinking there would be a much bigger sell off when the Billingham news hit. Only there wasn’t because nobody expected Billingham to happen. So now they are killing trading to stop becoming more out the money. If anyone wishes to pay significantly above the offer (and force their hand) we may well see.
I did just put my holding on a limit sell above 0.45… Just to check my nominees weren’t lending them…